Which is better, PME.AX or SIBN?

On the Buffett-Fit framework, Pro Medicus Limited (PME.AX) currently grades higher than SIBN — 78/100 (B grade) vs 37/100 (D). That said, "better" depends on which framework you trust — PME.AX wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith; SIBN wins on none. The full pillar breakdown is on this page.

Should I buy PME.AX or SIBN?

This page is an educational comparison, not investment advice. Both PME.AX and SIBN are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is PME.AX better than SIBN for value investing?

On the Buffett-style value-investing framework, PME.AX currently grades higher — 78/100 vs 37/100, a 41-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between PME.AX and SIBN on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). PME.AX currently scores 78/100 (B grade); SIBN scores 37/100 (D grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, PME.AX or SIBN?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. PME.AX and SIBN are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, PME.AX or SIBN?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are PME.AX and SIBN both Healthcare stocks?

Yes — both Pro Medicus Limited (PME.AX) and SI-BONE, Inc. (SIBN) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this PME.AX vs SIBN comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Pro Medicus Limited

PME.AX$17.13BHealthcare Market cap, Sector

SI-BONE

SIBN$817.8MHealthcare Market cap, Sector

Overall winner

Pro Medicus Limited

PME.AX 70 SIBN

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

PME.AX7wins

0winsSIBN

Warren Buffett

78B

F37

Benjamin Graham

90A

D56

Philip Fisher

98A

D55

Peter Lynch

100A

F40

Joel Greenblatt

84B

Charlie Munger

91A

F38

Terry Smith

96A

F37

Side-by-side metrics

Metric	PME.AX	SIBN
Market cap	Winner: $17.13B	$817.8M
P/E (TTM)	147.6x	- Winner
EV/EBIT	106.8x	- Winner
ROIC (TTM)	Winner: 42.56%	-8.99%
Gross margin	Winner: 99.85%	79.59%
Net margin	Winner: 54.12%	-8.1%
Revenue CAGR 5y	Winner: 31.61%	22.18%
EPS CAGR 5y	37.34%	-
Debt / Equity	Winner: 0.0x	0.0x
Dividend yield	-	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

PME.AX leads on

ROIC (TTM)42.56%vs -8.99%+121%
Net margin54.12%vs -8.1%+115%
Market cap$17.13Bvs $817.8M+95%
Debt / Equity0.0xvs 0.0x+79%

SIBN leads on

P/E (TTM)-vs 147.6x+125%
EV/EBIT-vs 106.8x+125%

More like PME.AX

PME.AX vs 1681.HK PME.AX vs SANOFICONR.NS PME.AX vs SANOFICONR.BO PME.AX vs CAMX.ST

More like SIBN

SIBN vs 1681.HK SIBN vs SANOFICONR.NS SIBN vs SANOFICONR.BO SIBN vs CAMX.ST

Read the full Buffett-Brain analysis for PME.AX Read the full Buffett-Brain analysis for SIBN

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

Pro Medicus Limited

PME.AX$17.13BHealthcare Market cap, Sector

SI-BONE

SIBN$817.8MHealthcare Market cap, Sector

Overall winner

Pro Medicus Limited

PME.AX 70 SIBN

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

PME.AX7wins

0winsSIBN

Warren Buffett

78B

F37

Benjamin Graham

90A

D56

Philip Fisher

98A

D55

Peter Lynch

100A

F40

Joel Greenblatt

84B

Charlie Munger

91A

F38

Terry Smith

96A

F37

Side-by-side metrics

Metric	PME.AX	SIBN
Market cap	Winner: $17.13B	$817.8M
P/E (TTM)	147.6x	- Winner
EV/EBIT	106.8x	- Winner
ROIC (TTM)	Winner: 42.56%	-8.99%
Gross margin	Winner: 99.85%	79.59%
Net margin	Winner: 54.12%	-8.1%
Revenue CAGR 5y	Winner: 31.61%	22.18%
EPS CAGR 5y	37.34%	-
Debt / Equity	Winner: 0.0x	0.0x
Dividend yield	-	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

PME.AX leads on

ROIC (TTM)42.56%vs -8.99%+121%
Net margin54.12%vs -8.1%+115%
Market cap$17.13Bvs $817.8M+95%
Debt / Equity0.0xvs 0.0x+79%

SIBN leads on

P/E (TTM)-vs 147.6x+125%
EV/EBIT-vs 106.8x+125%

More like PME.AX

PME.AX vs 1681.HK PME.AX vs SANOFICONR.NS PME.AX vs SANOFICONR.BO PME.AX vs CAMX.ST

More like SIBN

SIBN vs 1681.HK SIBN vs SANOFICONR.NS SIBN vs SANOFICONR.BO SIBN vs CAMX.ST

Read the full Buffett-Brain analysis for PME.AX Read the full Buffett-Brain analysis for SIBN

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.